Aytu BioPharma Inc. (AYTU)
NASDAQ (CM) NASDAQ (CM) Primary 
XMUN 
Aytu BioPharma, Inc. (AYTU) Q3 2026 Earnings Call Transcript
Aytu BioPharma, Inc. (AYTU) Q3 2026 Earnings Call Transcript
Aytu BioPharma, Inc. (AYTU) Reports Q3 Loss, Tops Revenue Estimates
Aytu BioPharma, Inc. (AYTU) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to earnings of $0.2 per share a year ago.
Aytu BioPharma, Inc. (AYTU) Q2 2026 Earnings Call Transcript
Aytu BioPharma, Inc. (AYTU) Q2 2026 Earnings Call Transcript
Aytu BioPharma Inc. (AYTU) Reports Q2 Loss, Beats Revenue Estimates
Aytu BioPharma Inc. (AYTU) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.28 per share a year ago.
Aytu BioPharma, Inc. (AYTU) Q1 2026 Earnings Call Transcript
Aytu BioPharma, Inc. ( AYTU ) Q1 2026 Earnings Call November 13, 2025 4:30 PM EST Company Participants Joshua Disbrow - CEO & Director Ryan J. Selhorn - CFO, Corporate Secretary & Treasurer Conference Call Participants Robert Blum - Lytham Partners, LLC Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Nazibur Rahman - Maxim Group LLC, Research Division Edward Woo - Ascendiant Capital Markets LLC, Research Division Presentation Operator Greetings.
Aytu BioPharma Inc. (AYTU) Reports Q1 Loss, Tops Revenue Estimates
Aytu BioPharma Inc. (AYTU) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.2 per share a year ago.
Aytu BioPharma, Inc. (AYTU) Q4 2025 Earnings Call Transcript
Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q4 2025 Earnings Call September 23, 2025 4:30 PM EDT Company Participants Joshua Disbrow - CEO & Director Ryan J. Selhorn - CFO, Corporate Secretary & Treasurer Conference Call Participants Robert Blum - Lytham Partners, LLC Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Nazibur Rahman - Maxim Group LLC, Research Division Edward Woo - Ascendiant Capital Markets LLC, Research Division Presentation Operator Greetings.
Aytu BioPharma, Inc. (Aytu ) Q3 2025 Earnings Call Transcript
Aytu BioPharma, Inc. (Aytu ) Q3 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Robert Blum - Investor Relations, Lytham Partners Josh Disbrow - Chief Executive Officer Ryan Selhorn - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Operator Greetings. And welcome to the Aytu BioPharma Fiscal 2025 Q3 Earnings Call.
Aytu BioPharma, Inc. (AYTU) Q2 2025 Earnings Call Transcript
Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q2 2025 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Robert Blum - Investor Relations, Lytham Partners Josh Disbrow - Chief Executive Officer Ryan Selhorn - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Operator Good day, everyone, and welcome to the Aytu BioPharma Fiscal 2025 Q2 Earnings Call. At this time, all participants have been placed on a listen-only.
Aytu BioPharma Disclosure Notification
DENVER, CO / ACCESSWIRE / December 3, 2024 / SUMMARY NOTICE OF PENDENCY OF DERIVATIVE ACTION, AGREEMENT OF SETTLEMENT AND RELEASE WITH RESPECT TO CERTAIN PARTIES, AND SETTLEMENT HEARING IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE LITIGATION STYLED WITMER V. ARMISTICE CAPITAL LLC, ET AL.
Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM)
DENVER, CO / ACCESSWIRE / November 22, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced it ranked 380th on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year. "We are honored to be recognized for the fourth consecutive year as a member of the Deloitte Technology Fast 500 list of the most rapidly growing companies," commented Josh Disbrow, Chief Executive Officer of Aytu BioPharma.
Aytu BioPharma, Inc. (AYTU) Q1 2025 Earnings Call Transcript
Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q1 2025 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Robert Blum - IR, Lytham Partners Josh Disbrow - Chief Executive Officer Mark Oki - Outgoing Chief Financial Officer Ryan Selhorn - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Operator Greetings. Welcome to the Aytu BioPharma Fiscal 2025 Q1 Earnings Conference Call.
